

THE BLOOD SERVICE'S YEAR

2019



**LINK IN
A CHAIN OF
HELPERS**

Finnish Red Cross
Blood Service





More
information:
[http://
vuosikertomus.
veripalvelu.fi/en](http://vuosikertomus.veripalvelu.fi/en)

CONTENTS:

The Blood Service in a nutshell	2
Our values	4
Review by the Chief Executive	4
Operational reviews	6
Finances and social responsibility.....	16
Personnel	18

THE BLOOD SERVICE IN A NUTSHELL

THE BLOOD SERVICE IN THE FINNISH HEALTHCARE SYSTEM

■ The Blood Service is part of the Finnish Red Cross and serves Finnish healthcare. We are responsible for supplying blood products all over Finland in a centralised manner. Our tasks include organising blood donations and collecting blood as well as testing donated blood, manufacturing blood products and distributing them to hospitals.

We provide healthcare sector services such as blood cross-matching and tests needed for organ, tissue and stem cell transplants. The Blood Service performs blood group and blood group antibody tests for all pregnant women. The Blood Service also hosts the Finnish Stem Cell Registry, which provides stem cell grafts for patients.

Our strong expertise is built on in-house research and development, which forms the foundation for safe blood transfusions and novel cell therapies now and in the future.

We help others to save lives. We operate together with voluntary donors and hospital professionals. •



PRODUCTION AND LAYOUT:
Mediafocus Oy
TEXTS: FRCBS Communications
KUVAT: FRCBS
PRINTING HOUSE: Grano Oy



Helping patients is a joint effort

We work to help patients get better. Together with blood donors, the Blood Service supports hospitals in treating patients. A host of volunteers assists us in organising blood donation events.

We are expert professionals

The Blood Service operates in 9 towns and cities and employs about 500 professionals, all experts in their field. We provide blood and cell products and associated laboratory and expert services for the health-care system.

We are a non-profit organisation

The Blood Service is an independent, non-profit unit of the Finnish Red Cross. We cover the costs of our operations and their development by selling cell and blood products and expert services to the Finnish healthcare system. We are responsible for maintaining good operational efficiency and overall economic efficiency.



© SHAUN DUNCAN





REVIEW BY THE CHIEF EXECUTIVE

OUR VALUES

PATIENT WELL-BEING

The aim of our operations is always the well-being of patients.

RESPECT FOR DONORS

Voluntary blood and stem cell donors are important partners in the chain through which the Blood Service provides its help. We value donors and their gift highly and want to provide a channel through which they can help patients.

RELIABILITY

Trust is earned and nurtured by applying clear, consistent practices. We exercise good corporate governance and transparent communications.

WORKING COMMUNITY WELL-BEING

We seek to develop our personnel's well-being to achieve optimal results in our operations. We want to ensure that our personnel consider the Blood Service a good place to work, a place where they can succeed and where they enjoy their work while being supported in continuous development.

OPERATIONAL EFFICIENCY

We value the gift given by donors and do our best to ensure it is used at the right time and as effectively and appropriately as possible for the benefit of patients. We also continually develop our operations to make them run as smoothly as possible.

As before, the national supply reliability of blood products remained good throughout the year. There were no major supply problems. The Stem Cell Registry was also able to meet demands in the search for matching stem cell donors to help patients with severe blood disorders.

We prepare for the future in many ways. In September, an important decision was made to relocate the Blood Service's main place of business in autumn 2022 into new premises being built in Vehkala, Vantaa. The new premises will allow for even smoother production, laboratory and storage processes. At the same time, we will enhance our preparedness for exceptional circumstances.

For a few years, we have been preparing for the introduction of a new data system for the management of blood donation, production and the supply chain. The introduction is scheduled for 2020. The first thing about the new system that blood donors will see is the opportunity to fill in the health questionnaire online before arriving to donate blood.

The Board of the FRC has approved the Blood Service's research and development strategy. The aim is to improve the quality, safety, availability and effective use of current and future products and services. One target is to improve the efficiency of the service chain.

We conduct our research vigorously and actively. December saw completion of the 64th doctoral dissertation within the Blood Service. Sami Valkonen, MA, conducted his dissertation on the biology of microves-



icles, which are vesicles derived from red blood cells and platelets. Research continues in the form of a national project to investigate whether these vesicles could be used in transporting medicinal agents in the body.

In our product development, new areas for development include products used in gene and cell therapy. In the future, it is hoped this will offer treatment options for diseases previously thought to be incurable. We have the resources to transfer the process from research laboratory to production in collaboration with the University of Helsinki and the Hospital District of Helsinki and Uusimaa.

One of the ten biobanks in Finland operates within the Blood Service. Biobanks give samples and data for high-quality research and product development projects. The biobank at the Blood Service participates in the national FinnGen project with the aim of utilising genomic and health information to bring about important innovations that will promote health.

The Blood Service gains the majority of its income by selling blood products and services to hospitals, by selling plasma unused in Finland to the pharmaceutical industry, and from asset investment. Our economic situation is solid despite the fact that the use of blood products has diminished by 40% in just over 20 years, and prices have not been increased for six years.

Our activities are non-profit, which in practice means that any surplus from financing our operations is used to develop Blood Service activities. In accordance with

Blood Service's main place will be in Vantaa in autumn 2022.

this principle, the surplus of previous years has been used to create an independent fund to support research activities. At the moment, its capital amounts to approximately EUR 23M. This allows us to ensure high-level research will continue for years to come.

I wish to offer our heartfelt thanks to the voluntary blood donors and members of the Stem Cell Registry who have made our work possible. We do our best to ensure that the gift you give will be of maximum benefit to its recipient. I also wish to thank our staff, who have worked tirelessly to make this possible. I also want to thank our clients and partners for their valuable collaboration.

Martti Syrjälä

Professor
Chief Executive of the Blood Service



OPERATIONAL REVIEWS


Blood group distribution among donors in Finland

New blood donors in 2019

A+	A-	B+	B-	AB+	AB-	O+	O-
35%	6%	15%	2%	7%	1%	29%	5%

Blood donors are invited to donate on the basis of their blood group.

Whole blood donations



In comparison with the previous year, less blood was collected, due to a decrease in the use of red blood cells in hospitals.

BLOOD DONATION

■ Blood donations were stable, and there were no surprising or major fluctuations in the need for blood products. The use of blood products in hospitals decreased slightly as in previous years, which naturally affected the amount of blood collected.

There were 198,339 whole blood donations, some 6,000 fewer than in the previous year. The number of automated platelet donations was 2,481, about one hundred fewer than in the previous year. The total number of all blood donations during the year was 200,822. A total of 124,843 persons arrived to donate blood, 114,353 of whom gave blood.


The proportion of first-time donors was 14.8%, the number being 18,526. To reach new blood donors, we worked together with educational institutions, the Finnish Defence Forces, communities and companies by organising blood donation campaigns.

53% of blood donations took place at Blood Service centres, while 47% were at blood donation events, 1,100 of which were organised around Finland.


Group blood donations are popular. The "BloodGroups", which are groups of people brought together by work, hobbies, studies or friendship, recorded over 21,000 donations – 40% more than in the previous year. A record number of 948 new groups were started, the highest number being during the autumn campaign. •



Number of donations per person in 2019



Blood donors' age and gender distribution in 2019



The group with the most blood donors is young women.



Blood product sales to hospitals

Product, units	2017	2018	2019	change % 2018-2019
Red blood cells (without white blood cells)	188,571	191,857	190,437	- 0.7%
Platelet products (including apheresis products)	34,131	33,366	31,621	- 5.2%

The use of blood products was down from the previous year.

Use of donated whole blood for preparation of blood products

	red blood cells	platelets **
Products used in blood transfusions	96%	91%
Removals related to blood donation	2%	-
Removals related to laboratory results and the manufacturing process	1%	-
Others not used for blood transfusions (expired or supplied for medicines manufacture)	1% *	9%

* Some red blood cells not used for blood transfusions are sent for use as raw material for a medicinal product used for the treatment of porphyria (a rare metabolic condition).

** Proportions of platelet products; manufactured using only some of the donated whole blood units.

In Finland, the use of blood for the treatment of patients is highly efficient.



BLOOD PRODUCTS

■ The manufacture of blood products involves separating the donated whole blood into red blood cells, platelets and plasma. We are responsible for the distribution of blood products to all Finnish hospitals in accordance with the needs of medical care.

In 2019, there were no surprises related to the need for blood products at hospitals. Thanks to good management of the order and supply chain, stock levels were optimal, and the donated blood was utilised efficiently for production.

The number of red blood cell products sold to clients for patient use was 190,437, less than one per cent below the figure for the previous year. The need for the other main product, platelet products (thrombocytes), diminished in hospitals by around five per cent, as expected. Sales of medicinal frozen plasma (octaplasLG) to hospitals by the Blood Service fell by almost seven per cent. The decrease is due to improved treatments. •



LABORATORY SERVICES

■ Our Laboratory Services conduct tests to ensure the safety and quality of the Blood Service's blood and cell products and to meet various healthcare needs.

In tissue compatibility testing, the rise in the number of organ transplants and haploidentical stem cell transplants contributed to increased test numbers. In contrast, in blood group assays, test numbers decreased slightly due to the fact that an increased proportion of blood compatibility tests and antibody identification tests are performed by hospital laboratories. The number of tests on maternity clinic specimens decreased along the fall in birth rate.

We are continuously developing our workflow processes in order to ensure the efficiency and responsibility of our operations. In 2019, we implemented a process-level change to reduce the number of sampling tubes taken during blood donations from four to three. This change resulted in a significant reduction in workload as well as the environmental burden of our operations by saving 200,000 sampling tubes annually.

We made a major reorganisation of our laboratory by transferring blood coagulation laboratory assays to the Finnish company Fimlab Laboratoriot Oy via transfer of business. The purpose was to ensure the continuity of bleeding and clotting tendency testing and platelet testing and their continued development in Finland. As part of this change, Fimlab took on the employees concerned. •

Blood Service laboratory tests for healthcare units

	2017	2018	2019
Tests for bleeding and thrombotic tendencies	10,491	10,346	6,707**
Tests for blood typing	14,433	13,992	12,623
Red blood cell antibody identification	4,374	4,279	3,990
Blood compatibility tests performed urgently and outside office hours	2,307	2,445	2,314
Tests on maternity clinic specimens	74,718	69,792	69,115
Tissue compatibility tests	11,880	9,423*	10,245
Platelet tests	533	564	378**

* The structure of the test package was changed in 2018.

** Bleeding and clotting tendency testing and platelet testing were transferred to Fimlab Laboratoriot Oy on 1 September 2019.

The fall in birth rate is reflected in the smaller number of tests on maternity clinic specimens.

HI and hepatitis (B and C) viruses and syphilis in blood donor samples

	2015	2016	2017	2018	2019
Hepatitis B	7	2	3	2	5
Hepatitis C	7	7	4	4	8
HIV	1	0	1	2	1
Syphilis	4	9	6	4	9

Careful donor selection ensures that very few carriers of the HI virus or hepatitis viruses are identified when the blood is tested for infection.

Organ transplants performed in Finland (Source: Scandiatransplant)

	2015	2016	2017	2018	2019
Kidney	244	262	240	238	293
Liver	77	61	63	66	64
Cardiac disorders	27	30	26	47	30
Lungs	24	18	24	18	27
Pancreas	17	27	21	23	39
Small intestine	3	0	0	0	0
Other	0	1	0	0	0
TOTAL	392	399	374	392	453
From deceased Finnish organ donors	127	136	116	108	141
From live Finnish organ donors (kidney)	15	22	29	32	25

The Blood Service performs tissue typing for all organ and stem cell transplants performed in Finland and assesses tissue compatibility between the transplant recipients and the organ donors.



Grafts delivered by the Stem Cell Registry

Grafts supplied, total			
	2017	2018	2019
Bone marrow graft	23	14	11
Blood stem cell graft	101	104	105
Cord blood graft	2	4	1
Lymphocyte graft	11	13	9
Total	137	135	126

There are various ways to collect stem cells from donors. Harvesting the cells from the donor's bloodstream is by far the most common method.

From a Finnish donor to a Finnish patient			
	2017	2018	2019
Bone marrow graft	7	5	0
Blood stem cell graft	20	18	21
Cord blood graft	1	0	1
Lymphocyte graft	2	2	0
Total	30	25	22

From a non-Finnish donor to a Finnish patient			
	2017	2018	2019
Bone marrow graft	11	8	8
Blood stem cell graft	66	54	58
Cord blood graft	0	2	1
Lymphocyte graft	6	8	8
Total	83	72	75

From a Finnish donor to a non-Finnish patient			
	2017	2018	2019
Bone marrow graft	3	1	3
Blood stem cell graft	8	13	12
Cord blood graft	1	2	0
Lymphocyte graft	1	3	0
Total	13	19	15


The Stem Cell Registry operates internationally. The Blood Service's couriers also bring in stem cell grafts from abroad.



STEM CELL REGISTRY

■ The Finnish Stem Cell Registry, which is maintained by the Blood Service, belongs to the global network of registries providing stem cell grafts. Our Registry closely supports the Finnish and Estonian stem cell transplant centres. We recruit voluntary donors to the Registry. We search for compatible donors for patients in need of a stem cell transplant in registers in Finland and other countries. We also organise graft collections from Finnish donors and supply the grafts to transplant centres.

5,345 new members joined the Stem Cell Registry, and at the end of the year we had over 52,000 members. The number has doubled in the past five years. We supplied 126 grafts to stem cell transplant centres treating patients. The Blood Service's couriers picked up 70 grafts from collection centres in other countries and delivered them to hospitals for the treatment of patients. •



MEDICAL SERVICES AND CONTACTS WITH CLIENT HOSPITALS

■ Our physicians participate in patient care by giving opinions and answering questions about the patient samples tested in the Blood Service laboratory. They also support hospitals during on-call times via telephone consultations on issues such as blood transfusions. Our contact network consists of healthcare professionals involved in blood transfusion treatments from all university and central hospitals.

In 2019, the preliminary report of a national collaborative project looking into the storage of data generated in blood transfusions in the Kanta service was completed. Improved utilisation of data would significantly help in the development of blood transfusion treatments. The project continues in the National Institute for Health and Welfare, with the Blood Service contributing actively to its development.

During the year, we arranged seven training events for healthcare professionals, and several other training events at clients' premises. Our experts were active in lecturing at educational events on subjects such as laboratory tests and the use of blood products. We provided information to our clients, particularly about the optimal use of O RH negative blood group products, also known as "emergency blood".

We regularly measure our clients' satisfaction by means of surveys. The 2019 client survey was targeted at laboratory clients. Hospitals rated the Blood Service excellent overall with a score of 9.4 on a scale from 4 to 10. •





ADVANCED CELL THERAPY CENTRE

■ Our Advanced Cell Therapy Centre researches, develops and manufactures new cell therapy products for use in healthcare. In 2019, we provided mesenchymal stromal cell products (LY-MS-C) to six patients for the treatment of immunological problems in the stem cell transplant units at Helsinki and Turku University Central Hospitals. We also continued manufacturing modified haploidentical stem cell grafts for paediatric patients.

We published four scientific publications, by ourselves and in collaboration with the University of Helsinki, Barcelona Blood Bank as well as research groups from Canada and the United States. Our new initiatives included projects to produce cell therapy products for the treatment of refractory cancers, a NK cell product, and a CAR T cell product. •



RESEARCH


■ The Blood Service's scientific research is guided by the goals specified in the research strategy:

- Biobank activities and research related to genomic data to promote research into blood donation-related health and public health
- Studying red blood cells and thrombocytes to ensure the safe use of blood products
- Research concerning blood, cell and tissue transplant compatibility to create a unified scientific basis for Blood Service laboratory activities
- Research into new cell therapies to support their introduction in practice

In 2019, we spent a total of 3.3 million euros on research, approximately half of which was covered by external funding. In 2019, Blood Service research staff published 26 peer-reviewed scientific publications. We had 11 PhD-level researchers.



Division of research working hours by study area in 2017-2019



Research in the areas of blood donation and biobank activities has grown.



A significant new initiative and resource for our research was a three-year grant from Business Finland for our project to study whether blood cell-derived vesicles, i.e. microvesicles, can be used in drug transportation in the treatment of severe disorders of the central nervous system. 13 Finnish partners are participating in the research consortium led by the Blood Service.

Our biobank has established its activities and is one of the key actors in research. The biobank has already recruited all of the blood donor samples needed; the goal was 50,000 samples.

The biobank's main client is the large-scale national FinnGen research project, for which over 30,000 samples have been supplied. The FinnGen project aims at gaining a comprehensive understanding of the hereditary background of diseases, particularly in the Finnish population by collecting 500,000 samples. Our researchers are helping to analyse the results, and the project findings will also be utilised in our own research. •

Number of scientific publications by research area

Strategy focus area	Total	2016	2017	2018	2019
Blood donation	11	3	2	2	4
Blood cells	8	1	2	1	4
Tissue compatibility	38	13	12	6	7
Cell therapy	31	14	4	6	7
Other areas	23	11	7	1	4
Total	111	42	27	16	26

The number of research publications varies annually depending on the stage the research projects are at.





OTHER OPERATIONS


■ Our **quality management** staff ensure the Blood Service's operations meet the requirements of the legislation, authorities, accreditation bodies and pharmaceutical industry stakeholders. In 2019, areas highlighted in the development of quality management were harmonising quality activities and making digital improvements. We introduced a new document management system as well as digital working processes for operating instructions

In the development of our **Digital Services**, we focused on process testing and preparations for the introduction of our new enterprise resource planning system, "Vein-to-vein". Introduction of the system is scheduled for 2020. Key projects also included improving information security and defining the workflow process for digital development.

In **Communications and Marketing**, we carried out several campaigns to encourage people to donate blood and join the Stem Cell Registry. Campaigns and partnerships were carried out in ice hockey and motor sports, for example. A collaboration project with the Finnish Driving Schools Association utilised information about blood donation in the study material and in the risk management training of future drivers.

The Blood Tattoo event in Helsinki was organised to communicate the effects of tattoos on blood donation and to clear up deeply-rooted misinformation. The event offered blood donors an opportunity to get a blood group tattoo designed by a tattoo artist, something that attracted a lot of positive attention.


Our communications on social media were particularly active in the past year, and we produced




several new videos to encourage people to help. Together with the Finnish Red Cross, we released a mobile application to help blood donors find donation sites and to check their eligibility to donate. •

© TIMO SAVELA


FINANCES AND SOCIAL RESPONSIBILITY



Blood products account for most of the Blood Service's turnover.



Personnel costs are the Blood Service's biggest single cost item.



The cost of a blood product consists of several factors.

The Blood Service is a non-profit organisation. Its activities are financed by the sales of products and services to health-care organisations. The Blood Service is not supported by government funds or other external sources, except for grants and subsidies for research projects. Any financial surplus is not shared but instead used to ensure the continuation and development of activities.

Net profit for the financial period was EUR 9.5 million. The majority of this, EUR 6.0 million, was financial revenues accruing from an increase in the value of investments. Turnover was €58.8 million, 2.7% down on the previous year. The decrease is due largely to a fall in sales of blood products. Other operating revenues include one-off sales revenue from the transfer of certain business operations.

Personnel costs were up by 1.1%. Material and subcontracting expenses were down by 2.3%. Other costs, the largest of which were incurred by premises, ICT and logistics services, increased by 3.2%.

The use of blood products has declined by some 25% in 10 years. The Blood Service has adjusted well to the situation, and there has been no need to increase the prices of blood products

Social responsibility indicators

	2017	2018	2019
ECONOMIC INDICATORS			
Turnover, €1,000	60,569	60,419	58,792
Materials and services, €1,000	-15,795	-15,558	-14,967
Personnel expenses, €1,000	-23,824	-23,987	-24,194
SOCIAL INDICATORS			
Number of personnel, full-time (FTE), average	431	428	425
Days lost through sickness	4,709	4,831	4,805
Accidents at work	28	34	25
Personnel training, €1,000	-275	-271	-247
Personnel training, €/person	622	615	558
Personnel satisfaction, Trust Index® total points (a Finnish Great Place to Work study)	77%	78%	81%
Satisfaction among blood donors, Net Promoter Score	91%	92%	92%
Client satisfaction (on a scale from 4 to 10)	9.3 n=107	9.3 n=151	9.4 n=74
ENVIRONMENTAL INDICATORS			
Electricity consumption, MWh *	6,107	6,207	6,043
Water consumption, m ³ *	11,599	10,975	11,268
District heat consumption, MWh *	4,801	4,748	4,303
Incinerable waste, kg *	57,100	57,912	52,720
Sorted municipal waste, kg **	157,300	183,956	174,693
Hazardous waste, kg *	8,000	10,111	6,844
Travel days	10,973	11,285	11,508
OTHER INDICATORS			
Number of blood donations (whole blood and aphereses)	204,948	206,610	200,822
Number of blood donors (whole blood and aphereses)	118,244	118,931	114,353
Persons registered at blood donations	130,411	131,465	124,843
Reported adverse reactions of blood transfusion	234	244	342
Grafts delivered by the Stem Cell Registry	137	135	126
Number of members in the Stem Cell Registry (31 December)	41,493	48,340	52,176

* Kivihaka, Helsinki, including municipal waste and energy consumption by the subtenants.

** Incinerable special biomedical waste also includes waste from Helsinki mobile blood collection unit.

since 2014. 2020 will also start with prices unchanged.

At the end of the financial year, the total capital as shown by the Blood Service's internal balance sheet was €86.4 million, of which €45.7 million was invested in securities. The bank balance was €32.9 million. The Board of Finnish Red Cross decided to create an independent fund to support research and development activities at the Blood Service. The initial

capital of the independent fund, formed from the surplus of previous years, amounted to €23.5 million.

The Blood Service prepares an internal profit and loss account and balance sheet on its operations. The Blood Service's financial result is included in that of the Finnish Red Cross, on which no auditor's report had been issued at the date of signing the Blood Service's balance sheet book. •

STAFF



Number of personnel

	2018	2019
Total number of personnel, 31 Dec.	510	491
Permanent	411	395
Temporary	72	69
On-call	27	27

Number of personnel, full-time (FTE), average	428	425
Number of personnel, average	514	513
Full-time employment, average	441	443

Distribution of personnel in the organisation (%)


	2019
Products and Medical Services	34%
Blood Donation	42%
Quality Management, Research and Product Development	11%
Support Services	12%

In 2019, the Blood Service had an average of 513 employees, whose contributions total the equivalent of 425 full-time employees (FTEs). The mean age of our employees was 43.1 years. Of our personnel, 87% were female and 13% male. Permanent employees had a mean duration of employment of 13.1 years, and the proportion of permanent employees who resigned was 4.2%.

The measures of well-being at work continued to be relatively good, as in previous years. The sickness absence rate in relation to theoretical working hours remained at 3.7%. The number of accidents at work declined from the previous year, totalling 25, of which 12 happened at the workplace and 13 on the way to or from work.

We continued target-oriented improvement of our workplace in accordance with the Great Place to Work® model. Our Trust Index® personnel survey total score increased for the sixth time in a row to 81%, which entitled us to our fourth Great Place to Work® certificate. For the second time, the Blood Service was nominated one of the best medium-sized workplaces in Finland with a ranking of 21st.

Our workplace development projects included the implementation of a success management model aimed at supporting the growth and development of teams and every Blood Service employee. We also carried out an extensive occupational health survey as the basis for a





project to improve well-being at work, including various training sessions, improved ergonomic aspects and support for personal ability to work. We also released a new employer image video to support the recruitment of new experts. •

Education demographics (%), 2019

NURSING Nurse, specialist nurse, public health nurse	40%
LABORATORY Clinical laboratory technologist, laboratory technician, laboratory analyst, medical laboratory technologist, special laboratory technician	16%
NATURAL SCIENCES B.Sc., M.Sc., Ph.Lic., Ph.D.	8%
SOCIAL SERVICES AND OTHER HEALTHCARE practical nurse, auxiliary nurse	8%
BUSINESS QBA, BBA, BSc (Econ)	6%
PHARMACY B.Sc. (Pharm), M.Sc. (Pharm), Pharmaceutical Assistant	6%
MEDICINE Lic.Med., D.Med.Sc., Specialist	3%
TECHNOLOGY M.Sc. (Technology), technician, other education in the field of technology	3%
Other education	10%

Sickness absences

	2017	2018	2019
Short absences due to sickness and accidents (days/person)	3.8	4.3	4.1
Absences due to sickness and accidents, total (days/person)	9.3	9.4	9.4
Sickness absence rate (% of theoretical working time)	3.7%	3.7%	3.7%

Finnish Red Cross
Blood Service



DONOR CENTRES

**BLOOD SERVICE CENTRE
HELSINKI, KIVIHAKA**
Kivihaantie 7, 00310 Helsinki
tel +358 29 300 1010

Donor information, free of charge
tel +358 800 0 5801
(weekdays, 8am–5pm)

ESPOO
Iso Omena Shopping Centre
Service Centre,
Suomenlahdentie 1
02230 Espoo

HELSINKI, SANOMA BUILDING
Töölönlahdenkatu 2
00100 Helsinki

JYVÄSKYLÄ
Kalevankatu 8, 40100 Jyväskylä

KUOPIO
Puijonkatu 23, 70100 Kuopio

LAHTI
Trio Shopping Centre
Hansakuja Kauppakatu 10
15140 Lahti

OULU
Isokatu 32 C, 90100 Oulu

SEINÄJOKI
Kauppakatu 26, 60100 Seinäjoki

TAMPERE
Koskikeskus Shopping Centre,
Hatanpään valtatie 1, 33100 Tampere

TURKU
Yliopistonkatu 29 b (3rd floor)
20100 Turku

The Blood Service also organises blood donation events every weekday in different places in Finland. More information on timings and venues on our website: www.bloodservice.fi.

www.bloodservice.fi

